|
|
|
signaling in cooperation with active Kras expression
1 Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; 2 Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; 3 Vanderbilt University Program in Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; 4 The Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, Tennessee 37232, USA
Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly lethal disease in humans. Transforming growth factor-
(TGF-
) signaling plays an important role in PDAC progression, as indicated by the fact that Smad4, which encodes a central signal mediator downstream from TGF-
, is deleted or mutated in 55% and the type II TGF-
receptor (Tgfbr2) gene is altered in a smaller subset of human PDAC. Pancreas-specific Tgfbr2 knockout mice have been generated, alone or in the context of active Kras (KrasG12D) expression, using the Cre-loxP system driven by the endogenous Ptf1a (pancreatic transcription factor-1a) locus. Pancreas-selective Tgfbr2 knockout alone gave no discernable phenotype in 1.5 yr. Pancreas-specific KrasG12D activation alone essentially generated only intraepithelial neoplasia within 1 yr. In contrast, the Tgfbr2 knockout combined with KrasG12D expression developed well-differentiated PDAC with 100% penetrance and a median survival of 59 d. Heterozygous deletion of Tgfbr2 with KrasG12D expression also developed PDAC, which indicated a haploinsufficiency of TGF-
signaling in this genetic context. The clinical and histopathological manifestations of the combined KrasG12D expression and Tgfbr2 knockout mice recapitulated human PDAC. The data show that blockade of TGF-
signaling and activated Ras signaling cooperate to promote PDAC progression.
[Keywords: Kras; pancreas-specific knockout; pancreatic ductal adenocarcinoma; Ptf1a; TGF-
; type II TGF-
receptor]
Received July 28, 2006; revised version accepted September 27, 2006.
Juntendo University, Tokyo 113-8421, Japan;
6 Osaka University, Osaka 565-0871, Japan.
E-MAIL hal.moses{at}vanderbilt.edu; FAX (615) 936-1790.
Supplemental material is available at http://www.genesdev.org.
Article is online at http://www.genesdev.org/cgi/doi/10.1101/NA
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G Feldmann, N Habbe, S Dhara, S Bisht, H Alvarez, V Fendrich, R Beaty, M Mullendore, C Karikari, N Bardeesy, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer Gut, October 1, 2008; 57(10): 1420 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, S. M. Vickers, N. V. Adsay, N. C. Jhala, H.-G. Kim, T. R. Schoeb, W. E. Grizzle, and C. A. Klug Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia Cancer Res., September 1, 2007; 67(17): 8121 - 8130. [Abstract] [Full Text] [PDF] |
||||